From candidate selection through to proof-of-concept
6 / 54 articles displayed
News
Quotient Clinical, the drug development services organization, announces its renaming to Quotient Sciences (Quotient), following the acquisitions of Co-Formulate, QS Pharma and SeaView Research. This new identity signifies a global footprint and an extended range of services, and symbolizes the commitment to ensuring a consistent and high-quality experience for customers.
News
Quotient Sciences has signed an agreement with Nuformix Technologies Limited to evaluate the clinical performance of Nuformix’ lead pharmaceutical cocrystal, NXP001, which is based on a currently marketed treatment in the field of oncology supportive care.
News
QS Pharma, a Quotient Clinical business, is now approved to manufacture medicinal products for the US, Europe and Japan.
Acquisition
Quotient Sciences, the early phase drug development services provider, today announces that it has acquired QS Pharma, the contract development and manufacturing organisation (CDMO), based near Philadelphia, US, from Charles River Laboratories International, Inc.
Acquisition
Quotient Sciences, the early phase drug development services provider, today announces that it has acquired SeaView Research.
News
Quotient Sciences, the innovative provider of early phase drug development services, is pleased to announce that Chief Compliance Officer, Simon Lee, has been elected as Secretary of the European CRO Federation (“EUCROF”).
